Maravai Lifesciences Holdings (MRVI) Income from Continuing Operations (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) recorded quarterly Income from Continuing Operations of 6377000.0 in Q1 2026, up 89.88% quarter-over-quarter from 63015000.0 in Q4 2025, and up 87.93% on a YoY basis from 3393204.21 in Q1 2025.
Maravai Lifesciences Holdings (MRVI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 6377000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 87.93% year-over-year to 6377000.0; the TTM figure through Mar 2026 stood at 184286000.0 (up 36.41% YoY), while the FY2025 annual figure was 230762000.0, up 11.12% from the prior year.
- Income from Continuing Operations was 6377000.0 for Q1 2026 at Maravai Lifesciences Holdings, up from 63015000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 156721000.0 in Q2 2022 to a low of 172455000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 8498411.76 across 5 years, with a median of 18420000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations soared 94.61% in 2022, then slumped 1582.49% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 87429000.0 in 2022, then sank by 225.8% to 109982000.0 in 2023, then surged by 58.11% to 46067000.0 in 2024, then slumped by 36.79% to 63015000.0 in 2025, then surged by 89.88% to 6377000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 6377000.0 (Q1 2026), 63015000.0 (Q4 2025), and 45057000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Maravai Lifesciences Holdings | 737.25 Mn | 728.85 Mn | 33.70 Mn | -6.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.38 Mn |
| Dec 31, 2025 | -63.02 Mn |
| Sep 30, 2025 | -45.06 Mn |
| Jun 30, 2025 | -69.84 Mn |
| Mar 31, 2025 | -52.85 Mn |
| Dec 31, 2024 | -46.07 Mn |
| Sep 30, 2024 | -172.46 Mn |
| Jun 30, 2024 | -18.42 Mn |
| Mar 31, 2024 | -22.68 Mn |
| Dec 31, 2023 | -109.98 Mn |
| Sep 30, 2023 | -15.10 Mn |
| Jun 30, 2023 | -11.94 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | 87.43 Mn |
| Sep 30, 2022 | 99.65 Mn |
| Jun 30, 2022 | 156.72 Mn |
| Mar 31, 2022 | 146.86 Mn |
| Dec 31, 2021 | 127.11 Mn |
| Sep 30, 2021 | 132.18 Mn |
| Jun 30, 2021 | 134.50 Mn |